# MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults

> **NCT00242411** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1900 (—)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Budesonide/Formoterol Turbuhaler
- **DRUG:** Conventional Best Asthma Therapy

## Key facts

- **NCT ID:** NCT00242411
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 1900 (—)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00242411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00242411, "MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00242411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*